Clinical Trials on Spherocytosis, Hereditary

Total 2610 results

Takeda

Recruiting

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland (CHOPIN)

Hereditary Angioedema (HAE)

Poland
Shire
Takeda Development Center Americas, Inc.

Recruiting

Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Hereditary Angioedema (HAE)

France, Austria, Australia, Spain, Czechia, Italy, United Kingdom, Germany, Israel, Ireland, Brazil, Denmark, Greece, Sweden
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America (EMPOWER)

Hereditary Angioedema (HAE)

Canada, United States, Puerto Rico
Takeda

Completed

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis (INTEGRATED)

Hereditary Angioedema (HAE)

France, Germany, Austria, Greece
Shire

Completed

Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

United States, Jordan, Canada
Shire
Dyax Corp.

Completed

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom
Shire

Withdrawn

Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)
BioCryst Pharmaceuticals

Completed

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

Hereditary Angioedema (HAE)

Austria, Denmark, France, Germany, Hungary, Israel, Italy, North Macedonia, Poland, Romania, Switzerland, United Kingdom
Shire

Completed

A European Post-Authorisation Observational Study Of Patients With Hereditary Angioedema

Hereditary Angioedema (HAE)

Germany, Spain, United Kingdom, France, Italy, Belgium
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
Octapharma

Not yet recruiting

Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Acute Hereditary Angio Edema
Hospital Universitari Vall d'Hebron Research Institute
Hospital Universitario La Paz

Not yet recruiting

Identification and Characterization of Genetic Variants in Hereditary Angioedema (GENOMAEH_01)

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Spain
First Affiliated Hospital of Fujian Medical University

Recruiting

PCSK9 Inhibitor Treatment for Patients With SPG5

Hereditary Spastic Paraplegia Type 5

China
CSL Behring

Completed

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Hereditary Angioedema Types I and II

Bulgaria, Hungary, Poland, Romania
Santhera Pharmaceuticals

Completed

Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy (RHODOS)

Leber's Hereditary Optic Neuropathy

Canada, Germany, United Kingdom
CSL Behring

Completed

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Hereditary Angioedema Types I and II

Germany
Medical University of Vienna

Completed

Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT

Fuchs' Endothelial Dystrophy

Austria
Centre Hospitalier Régional Metz-Thionville

Completed

Predictive Factors of Good Results After Primary Descemet's Membrane Endothelial Keratoplasty (DMEK) (GOODRMEK)

Endothelial Corneal Dystrophy
Unity Health Toronto
Sunnybrook Health Sciences Centre; University of Pittsburgh; Duke University; Barrow... and other collaborators

Active, not recruiting

Doxycycline for Hereditary Hemorrhagic Telangiectasia (HHT)

Hereditary Hemorrhagic Telangiectasia (HHT)

Canada
Imperial College London

Completed

Frequency of Common Medical Conditions in People With and Without HHT

Hereditary Hemorrhagic Telangiectasia (HHT)

United Kingdom
University Hospital, Essen

Completed

Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia

Hereditary Haemorrhagic Telangiectasia (HHT)

Germany
University Hospital, Grenoble

Recruiting

Status of Dental Care Practices in Patients With Hereditary Angioedema (PRADA)

Angio Edema Hereditary

France
Takeda

Recruiting

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Hereditary Angioedema (HAE)

Japan
Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II (ENABLE)

Hereditary Angioedema (HAE)

Germany, Switzerland, Spain, Israel, Italy, Austria, Portugal, Kuwait
Shire
Takeda

Completed

FIRAZYR General Drug Use-Results Survey (Japan)

Hereditary Angioedema (HAE)

Japan
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Hôpital Necker-Enfants Malades
European Georges Pompidou Hospital; CLAIROP

Completed

Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy (Béfinohl)

Safety Issues | Efficacy, Self

France
BioCryst Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan (APeX-J)

Hereditary Angioedema, HAE

Japan
Shire

Completed

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

United States
Shire

Completed

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Hereditary Angioedema (HAE)

United States, United Kingdom, Germany, Canada, Italy, Jordan, Puerto Rico
Shire

Completed

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Hereditary Angioedema (HAE)

Spain, Israel, United States, Hungary, Germany, Canada, Romania
Shire

Completed

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

Hereditary Angioedema (HAE)

United States, Germany, Hungary
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
Shire

Completed

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Hereditary Angioedema (HAE)

United States
Shire

Completed

Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema

Hereditary Angioedema (HAE)

Israel, Germany, Mexico, United States, Romania
Shire

Completed

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

Hereditary Angioedema (HAE)

Japan
Shire

Completed

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

Hereditary Angioedema (HAE)

United States, Jordan, Italy
BioCryst Pharmaceuticals

Completed

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema (APeX-1)

Hereditary Angioedema (HAE)

Canada, United Kingdom, Germany, Spain, Australia, Hungary, Italy, Austria, North Macedonia, Denmark, Switzerland
Edison Pharmaceuticals Inc

No longer available

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Leber's Hereditary Optic Neuropathy

United States
University Hospital, Essen

Completed

Immunmodulation in Patients With HHT

Hereditary Haemorrhagic Telangiectasia (HHT)

Germany
Singapore Eye Research Institute

Recruiting

The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery

Cataract | Fuchs' Endothelial Dystrophy

Singapore
University Health Network, Toronto

Active, not recruiting

Integrative Sequencing In Germline and Hereditary Tumours (INSIGHT)

Mutation | Hereditary Cancer Syndrome | High-Risk | Germline Mutation

Canada
Massachusetts Eye and Ear Infirmary

Completed

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

Cataract | Fuchs' Endothelial Dystrophy

United States
Legacy Health System
Lions VisionGift Research; Optovue; Devers Eye Institute

Terminated

Using the Optovue OCT to Select IOL Power

Cataract | Fuchs' Endothelial Dystrophy

United States
Stanford University
University of Pennsylvania; University of California, Davis; Oregon Health and... and other collaborators

Recruiting

Descemet Endothelial Thickness Comparison Trial II (DETECT II)

Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Fuchs

United States
Michael D. Straiko, MD
Lions VisionGift Research; Eye Bank Association of America

Recruiting

Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

Fuchs Endothelial Dystrophy

United States
Trefoil Therapeutics, Inc.

Completed

TTHX1114(NM141) in Combination With DWEK/DSO

Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Fuchs

United States
University of Illinois at Chicago

Withdrawn

Implementation of Population Breast Cancer Genetic Services in Federally Qualified Health Centers (FQHC) (TestMiGenes)

Hereditary Cancer Syndrome
Chigenovo Co., Ltd

Recruiting

Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy

Bietti's Crystalline Dystrophy

China
Oregon Health and Science University

Recruiting

OCT in Diagnosis of Irregular Corneas

Corneal Opacity | Keratoconus | Corneal Dystrophy

United States

Clinical Trials on Spherocytosis, Hereditary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations